Study Completion Times

May 01, 2011

Improved study completion times represents one of the most critical areas for clinical development organizations. Previous TTC research has demonstrated that paying sites more on a cost per patient basis does not improve study completions times.

Study Conduct: A Big Part of the Budget

May 01, 2010

The use of CROs to conduct clinical trials, including data management, has increased over the years and will most likely continue to represent a significant part of many companies' clinical research efforts. Consequently, sponsor companies need to be able to budget the costs of these outsourced studies as effectively as possible. No one is pleased when a sponsor company requests bids for a study, or asks a preferred provider to submit cost estimates and the lowest submitted figures are substantially above the amounts expected by the sponsor company.

Refutable Rates

May 01, 2010

Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.

How Overhead Rates Affect Negotiations in the UK

May 01, 2010

Institutional overhead remains one of the more contentious areas in clinical grant management. There can be substantial variations in these overhead rates from institution to institution with often times little immediately evident reason for the differences. Institution overhead rates in the United Kingdom seem to reflect that same imprecision.

Cost of Grants are on the Move

May 01, 2010

Clinical grant expenditures represent a major portion of the budget for later phase clinical trials. While the relative cost of conducting a clinical trial in a specific geography is not the sole driver in the decision of where to place study sites, relative costs do play a role.